Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

Gan & Lee Pharmaceuticals Denmark Finland Sweden China Germany Switzerland Italy United Kingdom Spain Netherlands Belgium France United States of America Austria

After 24 weeks of treatment in patients with Type 2 diabetes, the bi-weekly GLP-1 receptor agonist GZR18 injection showed superior efficacy in lowering HbA1c and body weight compared to semaglutide (Ozempic®).After 16 weeks of treatment in patients with Type 2 diabetes, the once-weekly insulin analog GZR4 injection demonstrated superior HbA1c reduction in patients with uncontrolled diabetes on basal insulins, compared to insulin degludec (Tresiba®).After 16 weeks of treatment in patients with Type 2 diabetes, the premixed dual insulin analog GZR101 injection showed superior efficacy in reducing HbA1c and postprandial glucose compared to insulin degludec/insulin aspart (Ryzodeg®).(Media) 
[e-mail]  (Business Development)
[e-mail] (Medical Information)

Photo - https://mma.prnewswire.com/media/2530786/image_5012475_31064389.jpg 
Logo - https://mma.prnewswire.com/media/2439708/4968030/Gan_Lee_Pharmaceuticals_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and-gzr101-injection-achieve-primary-endpoints-in-phase-2-clinical-studies-302276357.html